In clinical cancer, PRKACA participates in a fusion event with DNAJB1 in up to a hundred percent of fibrolamellar hepatocellular carcinoma and has therefore been identified as a suitable diagnostic marker for and a driver of oncogenic activities in that cancer [13,14,15]. Here, PRKACA is linked to cancer.